AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20510862 — intervention group
Group type: EXPERIMENTAL
Intervention: Model-based reinforcement learning
Number of subjects: 0
Study 20510862 — intervention group
Group type: EXPERIMENTAL
Intervention: Model-free reinforcement learning
Number of subjects: 0
Study 18575277 — intervention group
Group type: EXPERIMENTAL
Intervention: 100-g OGTT
Number of subjects: 41
Study 18575277 — intervention group
Group type: EXPERIMENTAL
Intervention: 75-g OGTT
Number of subjects: 41
Study 15909229 — intervention group
Group type: EXPERIMENTAL
Intervention: Omnilux Revive facial treatment (20 min treatments, three times a week for three weeks)
Number of subjects: 23
Study 15909229 — intervention group
Group type: EXPERIMENTAL
Intervention: Omnilux Revive facial treatment
Number of subjects: 23
Study 12217597 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 5mg/kg IV + Prednisone 40 mg/day for 28 days
Number of subjects: 20
Study 12217597 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Prednisone 40 mg/day for 28 days
Number of subjects: 20
Study 9929018 — intervention group
Group type: EXPERIMENTAL
Intervention: Conformal radiotherapy
Number of subjects: 225
Study 9929018 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy
Number of subjects: 225
Study 7779142 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine (30 mg t.i.d.) and Indometacin (25 mg b.i.d.)
Number of subjects: 24
Study 7779142 — intervention group
Group type: COMPARATOR
Intervention: Nimodipine monotherapy
Number of subjects: 24
Study 2087857 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval training (1:1 min work and interval)
Number of subjects: 18
Study 2087857 — intervention group
Group type: COMPARATOR
Intervention: Continuous training
Number of subjects: 18
Study 6253067 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide (600 mg/m2 every 3 weeks)
Number of subjects: 124
Study 6253067 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (600 mg/m2 every 3 weeks) and CCNU (70 mg/m2 every 6 weeks)
Number of subjects: 124
Study 6253067 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (600 mg/m2 every 3 weeks), CCNU (70 mg/m2 every 6 weeks), and doxorubicin (40 mg/m2 every 3 weeks)
Number of subjects: 124
Study 30612237 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial telephone counseling (PTC)
Number of subjects: 204
Study 30612237 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 204
Study 28338206 — intervention group
Group type: EXPERIMENTAL
Intervention: Embosphere microsphere artery embolization
Number of subjects: 128
Study 28338206 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy cases)
Number of subjects: 128
Study 25985708 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized treadmill exercise test
Number of subjects: 248
Study 23046274 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-chosen brief motivational intervention (BMI)
Number of subjects: 288
Study 23046274 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-chosen computer-delivered educational program
Number of subjects: 288
Study 23046274 — intervention group
Group type: COMPARATOR
Intervention: Researcher-assigned brief motivational intervention (BMI)
Number of subjects: 288
Study 23046274 — intervention group
Group type: COMPARATOR
Intervention: Researcher-assigned computer-delivered educational program
Number of subjects: 288
Study 21416145 — intervention group
Group type: EXPERIMENTAL
Intervention: Golfers
Number of subjects: 23
Study 21416145 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 23
Study 19351731 — intervention group
Group type: EXPERIMENTAL
Intervention: l-arginine/GHRH infusion
Number of subjects: 22
Study 19351731 — intervention group
Group type: EXPERIMENTAL
Intervention: l-arginine/GHRP-2 infusion
Number of subjects: 22
Study 19351731 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal visceral fat (AVF)
Number of subjects: 22
Study 19351731 — intervention group
Group type: EXPERIMENTAL
Intervention: IGF-I
Number of subjects: 22
Study 19351731 — intervention group
Group type: EXPERIMENTAL
Intervention: AVF
Number of subjects: 22
Study 18843793 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate protein restriction (0.95 g kg(‐1) of body weight per day) for 3 weeks
Number of subjects: 6
Study 18843793 — intervention group
Group type: COMPARATOR
Intervention: Severe calorie restriction without malnutrition
Number of subjects: 6
Study 16014883 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 731
Study 16014883 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 731
Study 12409984 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasudil 5 mg TID
Number of subjects: 170
Study 12409984 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasudil 10 mg TID
Number of subjects: 170
Study 12409984 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasudil 20 mg TID
Number of subjects: 170
Study 12409984 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasudil 40 mg TID
Number of subjects: 170
Study 12409984 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasudil (various doses)
Number of subjects: 170
Study 10461605 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole
Number of subjects: 38
Study 10461605 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine
Number of subjects: 38
Study 10461605 — intervention group
Group type: COMPARATOR
Intervention: Adenosine
Number of subjects: 38
Study 10461605 — intervention group
Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 38
Study 7625349 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistant Starch (RS) diets
Number of subjects: 6
Study 7625349 — intervention group
Group type: EXPERIMENTAL
Intervention: RS-supplemented diets
Number of subjects: 6
Study 2664140 — intervention group
Group type: COMPARATOR
Intervention: Olympia alloy
Number of subjects: 800
Study 2664140 — intervention group
Group type: COMPARATOR
Intervention: Alternative alloys (W‐1, Ceramalloy II, Micro‐Bond N/P2, Ticon)
Number of subjects: 800
Study 2664140 — intervention group
Group type: COMPARATOR
Intervention: Unrestored tooth (periodontal control)
Number of subjects: 800
Study 409315 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn sodium, administered for four weeks
Number of subjects: 12
Study 409315 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn sodium
Number of subjects: 12
Study 31399275 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvanted 0.5 μg total viral protein (TP) with Al(OH)3
Number of subjects: 135
Study 31399275 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvanted 1.0 μg total viral protein (TP) with Al(OH)3
Number of subjects: 135
Study 31399275 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-adjuvanted 1.0 μg total viral protein (TP)
Number of subjects: 135
Study 31399275 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety profile monitoring
Number of subjects: 135
Study 29229209 — intervention group
Group type: COMPARATOR
Intervention: AV-101 (l-4-chlorokynurenine) at doses of 30-1800mg (Phase 1A) and 360, 1080, 1440mg/day (Phase 1B) administered orally for 14 days.
Number of subjects: 86
Study 29229209 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered orally for 14 days.
Number of subjects: 86
Study 25646645 — intervention group
Group type: EXPERIMENTAL
Intervention: Health care-seeking behaviour of HIV-infected mothers
Number of subjects: 32
Study 25646645 — intervention group
Group type: EXPERIMENTAL
Intervention: Health care-seeking behaviour of male partners
Number of subjects: 32
Study 25646645 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant care-seeking behaviour
Number of subjects: 32
Study 25646645 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategies to improve health care access
Number of subjects: 32
Study 23241479 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral and implant naltrexone
Number of subjects: 68
Study 19593797 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP + bortezomib (Arm A: 1 mg/m²; Arm B: 1.3 mg/m²)
Number of subjects: 49
Study 19593797 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP + bortezomib (Arm A: 1.3 mg/m²; Arm B: 1.6 mg/m²)
Number of subjects: 49
Study 17073835 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil 10 mg
Number of subjects: 600
Study 15119909 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release carbamazepine (ERC-CBZ) at a mean dose of 756.44 mg/day
Number of subjects: 204
Study 15119909 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release carbamazepine (ERC-CBZ)
Number of subjects: 204
Study 15119909 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study 11944742 — intervention group
Group type: EXPERIMENTAL
Intervention: Johnstone Pressure Splints
Number of subjects: 26
Study 11944742 — intervention group
Group type: COMPARATOR
Intervention: Neuromuscular rehabilitation
Number of subjects: 26
Study 9143576 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtotal gastrectomy
Number of subjects: 64
Study 9143576 — intervention group
Group type: COMPARATOR
Intervention: Total gastrectomy
Number of subjects: 64
Study 9143576 — intervention group
Group type: COMPARATOR
Intervention: Jejunal S-shaped pouch
Number of subjects: 64
Study 9143576 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 64
Study 8112490 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin and octreotide
Number of subjects: 0
Study 8112490 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockade
Number of subjects: 0
Study 8112490 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct control of the wedged hepatic vein pressure gradient
Number of subjects: 0
Study 8112490 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug treatment (general)
Number of subjects: 0
Study 8112490 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevention of recurrent hemorrhage
Number of subjects: 0
Study 2467135 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 2.5-5.0 mg (medium-dose group)
Number of subjects: 0
Study 2467135 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5.0-10.0 mg (high-dose group)
Number of subjects: 0
Study 2467135 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 1.25-2.5 mg (low-dose group)
Number of subjects: 0
Study 2467135 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29569754 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic bone substitute covered with a collagen membrane
Number of subjects: 15
Study 29569754 — intervention group
Group type: COMPARATOR
Intervention: Blood clot covered with a collagen membrane
Number of subjects: 15
Study 28349344 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-session intensive telephone counseling
Number of subjects: 384
Study 28349344 — intervention group
Group type: COMPARATOR
Intervention: Referral to state quitline counseling
Number of subjects: 384
Study 26476466 — intervention group
Group type: EXPERIMENTAL
Intervention: BreastCARE intervention
Number of subjects: 1235
Study 26476466 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1235
Study 26476466 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 1235
Study 24568169 — intervention group
Group type: EXPERIMENTAL
Intervention: Water flosser
Number of subjects: 40
Study 24568169 — intervention group
Group type: COMPARATOR
Intervention: Traditional string floss
Number of subjects: 40
Study 21353674 — intervention group
Group type: EXPERIMENTAL
Intervention: L-menthol (160 mg)
Number of subjects: 87
Study 21353674 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 17955021 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine
Number of subjects: 24
Study 17955021 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 17072702 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 microg oral clonidine and 20 mg raftidine (clonidine group; n = 41)
Number of subjects: 82
Study 17072702 — intervention group
Group type: COMPARATOR
Intervention: 20 mg raftidine only (control group; n = 41)
Number of subjects: 82
Study 14574247 — intervention group
Group type: EXPERIMENTAL
Intervention: Explant technique of scleral buckling
Number of subjects: 0
Study 14574247 — intervention group
Group type: COMPARATOR
Intervention: Implant technique of scleral buckling
Number of subjects: 0
Study 14574247 — intervention group
Group type: EXPERIMENTAL
Intervention: Both implant and explant techniques
Number of subjects: 0
Study 10997364 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of 100,000 IU vitamin A
Number of subjects: 120
Study 8959519 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg b.i.d.) plus Amoxycillin (750 mg t.i.d.) for 2 weeks
Number of subjects: 450
Study 8959519 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (40 mg b.i.d.) plus Clarithromycin (500 mg t.i.d.) for 2 weeks
Number of subjects: 450
Study 8959519 — intervention group
Group type: EXPERIMENTAL
Intervention: Second consecutive dual therapy (either omeprazole plus amoxycillin or omeprazole plus clarithromycin)
Number of subjects: 450
Study 8959519 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall eradication rates
Number of subjects: 450
Study 8959519 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with gastric ulcer (GU)
Number of subjects: 450
Study 1526681 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefodizime (CDZ) 1 g i.m. b.i.d. for eight days
Number of subjects: 20
Study 1526681 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 4089792 — intervention group
Group type: COMPARATOR
Intervention: Heparin alone (Hep)
Number of subjects: 358
Study 4089792 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin + dihydroergotamine (DHE-Hep)
Number of subjects: 358
Study 4089792 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin + sulphinpyrazone (Sulph-Hep)
Number of subjects: 358
Study 29456238 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary PCI+RIPC
Number of subjects: 80
Study 27483317 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-pacing caloric-restriction (P-CR; 6 meals/day, >30% protein/day)
Number of subjects: 40
Study 27483317 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified protein-pacing caloric-restriction (mP-CR)
Number of subjects: 40
Study 27483317 — intervention group
Group type: COMPARATOR
Intervention: Heart healthy (HH) diet (3 meals/day, 15% protein/day)
Number of subjects: 40
Study 24113340 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency repetitive transcranial magnetic stimulation on the left premotor cortex
Number of subjects: 0
Study 24113340 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of high-frequency repetitive transcranial magnetic stimulation and traditional eye-hand integration training
Number of subjects: 0
Study 24113340 — intervention group
Group type: COMPARATOR
Intervention: Traditional eye-hand integration training
Number of subjects: 0
Study 24113340 — intervention group
Group type: COMPARATOR
Intervention: High-frequency repetitive transcranial magnetic stimulation on the right premotor cortex
Number of subjects: 0
Study 22072742 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 361
Study 22072742 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 361
Study 20685066 — intervention group
Group type: EXPERIMENTAL
Intervention: Four Habits Coding Scheme (4HCS)
Number of subjects: 497
Study 18195202 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergocalciferol, 1000 IU/d, plus calcium citrate, 1000 mg/d
Number of subjects: 302
Study 18195202 — intervention group
Group type: COMPARATOR
Intervention: Calcium citrate, 1000 mg/d (control group)
Number of subjects: 302
Study 15903123 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin (QT-positive control)
Number of subjects: 48
Study 15903123 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfuzosin (40 mg)
Number of subjects: 48
Study 12553387 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental (7 mg kg(‐1)), fentanyl (2 microg kg(‐1)), succinylcholine (1.5 mg kg(‐1))
Number of subjects: 39
Study 12553387 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental (7 mg kg(‐1)), succinylcholine (1.5 mg kg(‐1))
Number of subjects: 39
Study 12553387 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental (7 mg kg(‐1)), fentanyl (2 microg kg(‐1)), cisatracurium (0.1 mg kg(‐1))
Number of subjects: 39
Study 10750600 — intervention group
Group type: COMPARATOR
Intervention: Exercise vigorous enough to work up a sweat less than once per week
Number of subjects: 22071
Study 10750600 — intervention group
Group type: COMPARATOR
Intervention: Exercise vigorous enough to work up a sweat once per week
Number of subjects: 22071
Study 10750600 — intervention group
Group type: COMPARATOR
Intervention: Exercise vigorous enough to work up a sweat 2-4 times per week
Number of subjects: 22071
Study 10750600 — intervention group
Group type: COMPARATOR
Intervention: Exercise vigorous enough to work up a sweat 5+ times per week
Number of subjects: 22071
Study 8668409 — intervention group
Group type: EXPERIMENTAL
Intervention: Dust control intervention (cleaning supplies, information, and demonstration)
Number of subjects: 104
Study 8668409 — intervention group
Group type: COMPARATOR
Intervention: Control group (brochure about lead poisoning prevention)
Number of subjects: 104
Study 8668409 — intervention group
Group type: EXPERIMENTAL
Intervention: Dust control intervention
Number of subjects: 104
Study 8668409 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 104
Study 1893699 — intervention group
Group type: EXPERIMENTAL
Intervention: Female condom (Reality)
Number of subjects: 30
Study 1893699 — intervention group
Group type: COMPARATOR
Intervention: Diaphragm
Number of subjects: 30
Study 6222756 — intervention group
Group type: EXPERIMENTAL
Intervention: I% metronidazole cream
Number of subjects: 51
Study 6222756 — intervention group
Group type: COMPARATOR
Intervention: 250 mg oxytetracycline tablets taken twice daily
Number of subjects: 51
Study 31138221 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal immediately following 1 h of moderate exercise (65% maximal heart rate)
Number of subjects: 12
Study 31138221 — intervention group
Group type: COMPARATOR
Intervention: High-fat meal alone (resting control)
Number of subjects: 12
Study 28625512 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-dose edoxaban regimen (HDER)
Number of subjects: 169
Study 28625512 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-dose edoxaban regimen (LDER)
Number of subjects: 169
Study 28625512 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 169
Study 26039949 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching with Valsalva maneuver
Number of subjects: 15
Study 26039949 — intervention group
Group type: COMPARATOR
Intervention: Stretching without Valsalva maneuver
Number of subjects: 15
Study 23615791 — intervention group
Group type: EXPERIMENTAL
Intervention: TB‐402 25 mg
Number of subjects: 0
Study 23615791 — intervention group
Group type: EXPERIMENTAL
Intervention: TB‐402 50 mg
Number of subjects: 0
Study 23615791 — intervention group
Group type: COMPARATOR
Intervention: Rivaroxaban 10 mg
Number of subjects: 0
Study 22058101 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg dalfampridine under fasted condition (no food for 10-12 hours)
Number of subjects: 30
Study 22058101 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg dalfampridine under fed condition (after a high-fat meal)
Number of subjects: 30
Study 22058101 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events reported by participants
Number of subjects: 30
Study 18667112 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education intervention for 18 months
Number of subjects: 140
Study 18667112 — intervention group
Group type: COMPARATOR
Intervention: Usual diet (Control)
Number of subjects: 140
Study 17537085 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal sacrocolpopexy with Burch colposuspension
Number of subjects: 322
Study 17537085 — intervention group
Group type: COMPARATOR
Intervention: Abdominal sacrocolpopexy without Burch colposuspension
Number of subjects: 322
Study 15565080 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal 1A (plain porridge with lean pork)
Number of subjects: 24
Study 15565080 — intervention group
Group type: COMPARATOR
Intervention: Meal 3A (plain noodles in clear soup)
Number of subjects: 24
Study 15222825 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intentions for home blood glucose monitoring, 4 times daily for 3 weeks
Number of subjects: 31
Study 15222825 — intervention group
Group type: COMPARATOR
Intervention: Rehearsed or deliberated (comparison groups)
Number of subjects: 31
Study 10909485 — intervention group
Group type: EXPERIMENTAL
Intervention: NAT2* genotype (slow acetylation)
Number of subjects: 266
Study 10909485 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (no NAT2* genotype)
Number of subjects: 266
Study 8547077 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 micrograms/kg rhIL-3
Number of subjects: 30
Study 8547077 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 micrograms/kg rhIL-3
Number of subjects: 30
Study 8547077 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0 micrograms/kg rhIL-3
Number of subjects: 30
Study 8547077 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 micrograms/kg rhIL-3
Number of subjects: 30
Study 8547077 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 micrograms/kg rhIL-3
Number of subjects: 30
Study 8547077 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of rhIL-3
Number of subjects: 30
Study 2023200 — intervention group
Group type: EXPERIMENTAL
Intervention: Inservice education for PHN
Number of subjects: 37
Study 2023200 — intervention group
Group type: COMPARATOR
Intervention: Public and physician information interventions
Number of subjects: 37
Study 6111216 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive-pressure tympanograms
Number of subjects: 0
Study 6111216 — intervention group
Group type: EXPERIMENTAL
Intervention: Type B tympanograms
Number of subjects: 0
Study 6111216 — intervention group
Group type: COMPARATOR
Intervention: Antihistamine-decongestant
Number of subjects: 0
Study 6111216 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31881952 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised training (FA), n=53, 50-min exercise circuit including strength and aerobic exercises, complemented with 30-min brisk walking on the third day.
Number of subjects: 144